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Hyperthermia in Clinical Oncology 
H.S . Reinhold and J. Overgaard 
THE CLINICAL application of hyperthermia has a strong biological 
rationale [l-3]. Experimental and clinical studies indicate that 
tumour control rates can be significantly enhanced if, for exam- 
ple, radiation therapy is combined with hyperthermia [4, 51. If 
a tumour is heated one or more times to a temperature of 43°C 
or higher for an hour, the probability of response or permanent 
control increases substantially. 
Nevertheless, some important problems remain. After about 
15 years of experiments and technological developments in heat 
delivery and temperature measurement, it is clear that the 
application of a hyperthermic dose of sufficient intensity to a 
tumour is not simple. In the past the tumour temperature was 
measured with one thermocouple several times to give the 
“tumour temperature”. Nowadays continuous multipoint ther- 
mometry is available, which indicates that it is not justified 
to speak about the tumour temperature but rather about a 
distribution of temperatures, which is heterogeneous not only 
in tumour space but also in treatment time. At the fifth European 
BSD-Users conference, in Noordwijk aan Zee and Rotterdam, 
The Netherlands (18-19 May 1990), which focused mainly on 
the clinical application of loco-regional hyperthermia as an 
adjuvant to radiotherapy or chemotherapy, T-90 (the tempera- 
ture reached in time and space by 90% of the sampled points) 
emerged as one of the better indices of the efficiency of hyperther- 
mia and therefore the therapeutic outcome [6, 71. The hyper- 
thermic level achieved depends not only on the amount of energy 
deposited in the tumour tissue but also on the cooling effect of 
blood flow [8, 91. Many heating methods have been tried: 
electromagnetic devices (refs. l&12 and L. Baert et al.), ultra- 
sound [13], systems based on interstitial brachytherapy [14, 
151 and perfusions with heated solutions [16, 171. Important 
advances reported at the meeting included online evaluation of 
temperature distribution of modern hyperthermia equipment in 
conjunction with the development of mathematical models (refs. 
18 and 19 and A.P.M. Zwamborn and P.M. van den Berg) to 
optimize heat application during treatment [20, 211. For the 
immediate future it seems realistic to add non-invasive thermom- 
etry to the hyperthermia equipment as an important aid in 
localizing power distribution in the patient. 
Apart from these technological developments, a serious con- 
cern was whether currently used experimental tumour systems 
are of any value for clinical research in hyperthermia (ref. 8 and 
S.B. Field et al.). This is a key issue because progress in clinical 
hyperthermia, with its strong dependence on factors such as 
sequence and interval with radiation [2] and chemotherapy [22], 
is derived from animal models [2]. Thus the question of the 
number of hyperthermia treatments required for optimum 
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effect, as well as the sequence and interval between the modalit- 
ies, is much discussed [23]. No consensus was reached at the 
meeting, other than that the treatment should be at a sufficiently 
high temperature (preferably 43°C) and last for about an hour. 
An encouraging observation is that all the retrospective analy- 
ses of superficial hyperthermia (e.g. carcinoma of the breast and 
recurrences of this tumour [4, 241 and head and neck nodes) 
indicate that with increasing hyperthermia treatment level, 
significantly higher response rates are obtained [6, 7, 251. In 
addition, some prolonged complete responses in pelvic chondro- 
sarcoma were reported by the paediatric oncology service in 
Paris. The current indications for successful adjuvant deep 
hyperthermia are found mainly in sarcomas [6, 24-261 and 
abdominal carcinomas, especially those of the cervix, colon and 
rectum [24]. There is also a need to improve the present results 
in bladder carcinoma [27]. In addition, an increasing number 
of encouraging results with thermochemotherapy, applied 
regionally or with perfusion, are being reported [ 171. The 
meeting emphasized that hyperthermia is finding a definite place 
in the treatment of cancer. 
As regards assessing the impact of hyperthermia on health 
care, a prospective cost-benefit analysis is being done by the 
Department of Economics at Erasmus University, Rotterdam, 
based on the results from the Rotterdam phase III trial on 
loco-regional hyperthermia plus radiotherapy. Such analysis is 
important: determining the value of a new, cost-increasing 
treatment modality [28]. Preliminary findings suggest that for 
pelvic tumours the costs may be moderate (about 1800 ECU per 
life year saved). 
The meeting emphasized that deep heating for the treatment 
of pelvic malignancies has become feasible, and that the results 
are encouraging. The Rotterdam phase III trial with the BSD- 
2000 machine has been started to identify whether addition of 
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News 
Tumour Response Monitoring 
A symposium on Tumour Response Monitoring and Treatment 
Planning will be held in Munich on 11-13 April 1991 to discuss 
recent advances and current developments in the field. The 
chairman of the symposium is Professor A. Breit and the meeting 
has been organised in close collaboration with the World Health 
Organization. Further information can be obtained from: ART 
91 Scientific Secretariat, Institute fiir Radiologische Onkologie 
der TU, Ismaninger Strasse 15, D-8000 Munchen 80, Federal 
Republic of Germany. Tel (49) 89 4140 43 05, fax (49) 89 4140 
43 96. 
EORTC Addresses 
A reminder of the new EORTC addresses. The EORTC Execu- 
tive Office is at 83 Avenue Mounier-Bte 10, B-1200 Brussels, 
Belgium-tel(32) 2774 16 40, fax (32) 2 772 36 75. The EORTC 
Data Center is at 83 Avenue Mounier-Bte 11, B-1200 Brussels, 
Belgium-tel(32) 2 774 16 11 (randomisation only [32] 2 774 16 
16) fax (32) 2 774 35 45. 
SociCtC Francais de RadiothCrapie 
Oncologique 
The Societe Fragais de Radiotherapie Oncologique will hold 
its first national congress in Paris on 22-23 November 1990. 
Further details can be obtained from the secretariat: SOCFI, 14 
rue Mandar, 75002 Paris, France. Tel (33) 1 42 33 89 94, fax 
(33) 140 26 04 44. 
European Osteosarcoma Intergroup 
The 16th meeting of the European Osteosarcoma Intergroup 
was held on 17 April 1990 at the Netherlands Cancer Institute. 
Dr J. van der Eijken was announced as the new chairman of the 
group. 
The Cambridge Data Centre reported on the progress of 
several protocols: 80861 has 239 patients with an average entry 
rate of 62 patients per year. So far 155 patients have stopped or 
completed therapy. A clear shift towards conservative surgery 
is indicated. 80862 has a total of 83 patients and further details 
